Bio-bibliographie (Englisch)

USA

Carl H. June

Balzanpreis 2025 für Gentherapie und genmodifizierte Zelltherapie

Für seine Erfindung und Entwicklung einer gentechnisch modifizierten Zelltherapie (CAR-T-Zellen), die bislang tödliche hämatologische Krebserkrankungen heilen konnte und vielversprechende Aussichten für die Behandlung von Autoimmunerkrankungen und soliden Tumoren bietet. Seine Arbeit hat den Weg für einen neuen Bereich der Zelltherapie und der synthetischen Biologie geebnet, der weitreichende Auswirkungen auf die Medizin hat.

Carl H. June, born in 1953, is an American citizen.

An immunologist and oncologist, he is currently the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine of the University of Pennsylvania.

He graduated from the US Naval Academy in 1975 and earned his medical degree from the Baylor College of Medicine in 1979. He spent his fourth year of medical school at the World Health Organization in Geneva, Switzerland, studying immunology and malaria with Dr. Paul Henri Lambert, and completed clinical training in internal medicine and medical oncology from 1979 to 1983 at the National Naval Medical Center in Bethesda, Maryland. June conducted postdoctoral research in transplantation biology with E. Donnall Thomas and John Hansen at the Fred Hutchinson Cancer Center in Seattle from 1983 to 1986. After completing his training, he returned to Bethesda, where he founded the Immune Cell Biology Program at the Naval Medical Research Center and was head of the department of immunology from 1990 to 1995. He was also a professor of medicine and of cell and molecular biology at the Uniformed Services University for the Health Sciences. In 1999 Carl June joined the University of Pennsylvania as a professor of molecular and cellular engineering at the University of Pennsylvania’s school of medicine and investigator at the Abramson Family Cancer Research Institute, where he remains today.

He is board-certified in internal medicine and oncology. Member of awards selection committees and of many Editorial Boards.

Among his main publications:

Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, Samanta M, Lakhal M, Gloss B, Danet-Desnoyers G, Campana D, Riley JL, Grupp SA, and June CH. Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo. Mol Ther. 2009;17(8):1453-64. 1491 citations.

Porter DL, Kalos M, Zheng Z, Levine B, and June C. Chimeric Antigen Receptor Therapy for B-cell Malignancies. Journal of Cancer. 2011;2:331-2. 4677 citations.

Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, and June CH. T cells expressing chimeric receptors establish memory and potent antitumor effects in patients with advanced leukemia. Science Translational Medicine. 2011;3(95):95ra73. 3308 citations.

Grupp SA, Kalos M, Barrett D, Aplenc R, Porter D, Rheingold S, Teachey D, Chew A, Hauck B, Wright J, Milone M, Levine B, and June C. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. New England Journal of Medicine. 2013;368(16):1509-18. 4318 citations.

Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, Gao P, Bandyopadhyay S, Sun H, Zhao Z, Lundh S, Pruteanu-Malinici I, Nobles CL, Maji S, Frey NV, Gill SI, Tian L, Kulikovskaya I, Gupta M, Ambrose DE, Davis MM, Fraietta JA, Brogdon JL, Young RM, Chew A, Levine BL, Siegel DL, Alanio C, Wherry EJ, Bushman FD, Lacey SF, Tan K, and June CH. Decade-long leukaemia remissions with persistence of CD4⁺ CAR T cells. Nature. 2022;602(7897):503-9. 715 citations.

Kawalekar OU, O’Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD, Jr., Patel PR, Guedan S, Scholler J, Keith B, Snyder NW, Blair IA, Milone MC, and June CH. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. Immunity. 2016;44(2):380-90. 1256 citations.

June CH, O’Connor RS, Kawalekar OU, Ghassemi S, and Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361-5. 2901 citations.

Good CR, Aznar MA, Kuramitsu S, Samareh P, Agarwal S, Donahue G, Ishiyama K, Wellhausen N, Rennels AK, Ma Y, Tian L, Guedan S, Alexander KA, Zhang Z, Rommel PC, Singh N, Glastad KM, Richardson MW, Watanabe K, Tanyi JL, O’Hara MH, Ruella M, Lacey SF, Moon EK, Schuster SJ, Albelda SM, Lanier LL, Young RM, Berger SL, and June CH. An NK-like CAR T cell transition in CAR T cell dysfunction. Cell. 2021;184(25):6081-100.e26.

Bai Z, Feng B, McClory SE, de Oliveira BC, Diorio C, Gregoire C, Tao B, Yang L, Zhao Z, Peng L, Sferruzza G, Zhou L, Zhou X, Kerr J, Baysoy A, Su G, Yang M, Camara PG, Chen S, Tang L, June CH, Melenhorst JJ, Grupp SA, and Fan R. Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission. Nature. 2024;634(8034):702-11.

Baker DJ, Arany Z, Baur JA, Epstein JA, and June CH. CAR T therapy beyond cancer: the evolution of a living drug. Nature. 2023;619(7971):707-15.